Questions And Answers About Bristol Myers Squibb's Consolidated Site Payments Strategy

Clinical trial payments can make or break sponsor-site relationships. IQVIA Technologies heard both perspectives on this issue from industry leaders George Kourtsounis, Senior Director for Clinical Trial Contracts and Grants at Bristol Myers Squibb (BMS); and Casey Orvin, Chief Commercial Officer at CenExel Clinical Research and former President of the Society for Clinical Research Sites during a recent webinar. During a Q&A session, these industry leaders lent their expertise to the following questions:

• What kind of oversight is in place at BMS, and what does that tell BMS about efficiencies and quality?
• Sponsors struggle with forecasting, as capabilities vary significantly across CROs. How does BMS feel about its current grant forecasting abilities?
• How can sites ensure they receive timely payments?
• What data sources are you receiving to forecast payments, and is it associated with specific trials?
• How has IQVIA CTP made payments easier for BMS?